Effect and safety of diluted vasopressin injection on bleeding during robot-assisted laparoscopic myomectomy: a protocol for a randomised controlled pilot trial

What Was Tested

This clinical study looks at Vasopressin.

Thus, this study was designed to compare the effect and safety of vasopressin injection on bleedings based on dilution levels of vasopressin with constant volumes during RALM.

Why It Was Studied

All potential subjects will be provided written informed consent.

The results of this study will be published in peer-reviewed journals and be presented at academic conferences.

Who Took Part

The study group was 39 patients.

PubMed tags the participants as women only.

This is a randomised controlled pilot trial, where a total of 39 patients will be randomly divided into three experimental groups in a 1:1:1 ratio.

How the Study Was Run

In design terms this was a randomized and pilot study.

Because people in this Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

It is described as a pilot, a small early test of whether a larger Vasopressin study would be practical.

As the primary endpoint, estimated blood loss would be compared.

As secondary endpoints, the researchers will check the level of haemoglobin and haematocrit, operation time, amount of transfusion, and the period of hospitalisation.

In addition, the researchers will check other complications related to vasopressin injection.

What Was Measured

The subject headings attached to it are Blood Loss, Surgical, Hemoglobins, Laparoscopy, Pilot Projects, Randomized Controlled Trials as Topic, Robotics and Saline Solution.

The authors tagged it with the keywords adult anaesthesia, gynaecology and minimally invasive surgery.

What This Means in Plain Language

The paper is a randomized and pilot study of Vasopressin in 39 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2022 (BMJ open), a journal based in England.

More context: the Vasopressin compound page, all human trials.